The process of monitoring and evaluating country and global pharmaceutical situations continues to evolve and to be improved. Determining which indicators and how many indicators should be used is a challenging and very complex process, and engenders much debate. Determining which indicators are the most useful depends on continuous field testing and continuous development of methodology for collecting and processing information.
The culture of monitoring among countries and stakeholders must also be promoted. Reliable, relevant data and information needs to be collected and the results reported to policy-makers and other players responsible for decisions relating to health systems planning, national drug policy implementation and allocation of technical, human and financial resources.